Bio-Techne Corp
TECH · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2017–FY2026
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- June
- Last updated
- Aug 2026
Headline figures
Bio-Techne Corp at a glance
In FY2026, Bio-Techne Corp reported revenue of USD 1,215,039 thousands, EBITDA of USD 349,249 thousands, EBITDA margin of 28.7%.
| USD thousands | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 1,219,635 | 1,215,039 | |||
| EBITDA | 212,158 | 349,249 | |||
| EBITDA margin | 17.4% | 28.7% | |||
| Free cash flow | 256,550 | 263,223 | |||
| ROIC | 3.5% | 9.2% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas